← Back to Search

Proteasome Inhibitor

Participants With MM for Multiple Myeloma

N/A
Recruiting
Research Sponsored by Takeda
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 6 months
Awards & highlights

Study Summary

In this study, people with MM will be treated with ixazomib citrate according to their clinic's standard practice. The main aim of the study is to check for side effects from ixazomib citrate.

Eligible Conditions
  • Multiple Myeloma

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Secondary outcome measures
Overall Response Rate (ORR)
Progression-free Survival (PFS)

Trial Design

1Treatment groups
Experimental Treatment
Group I: Participants With MMExperimental Treatment1 Intervention
Participants with MM who are newly prescribed and will start treatment with ixazomib citrate in a real-world clinical practice setting will be observed prospectively for up to 6 years 11 months.

Find a Location

Who is running the clinical trial?

TakedaLead Sponsor
1,207 Previous Clinical Trials
4,187,720 Total Patients Enrolled
50 Trials studying Multiple Myeloma
18,068 Patients Enrolled for Multiple Myeloma
Study DirectorStudy DirectorTakeda
1,218 Previous Clinical Trials
499,575 Total Patients Enrolled
25 Trials studying Multiple Myeloma
7,365 Patients Enrolled for Multiple Myeloma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)
2021. "A Study of Real-World Use of Ixazomib Citrate in People With Multiple Myeloma (MM)". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04840680.
~4 spots leftby Jun 2024
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top